In vitro pharmacological characterization of SPN-810M (molindone).

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Impulsive aggression (IA) is a reactive behavior often seen in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
• Currently, no FDA-approved medications specifically target IA, highlighting an unmet clinical need.
• The underlying mechanisms of IA are not fully understood but may involve dopamine, norepinephrine, and serotonin systems.

Purpose of the Study:

• To investigate the in vitro pharmacological profile of molindone (SPN-810M) as a potential treatment for IA.
• To elucidate the specific receptor interactions and mechanisms of action of molindone.

Main Methods:

• In vitro studies were conducted to assess the antagonist activity of molindone (SPN-810M) on dopamine and serotonin receptors.
• Pharmacological assays examined the effects of molindone and its metabolites on D2S, D2L, and 5-HT2B receptors.
• Studies also evaluated the influence of norepinephrine and dopamine neurotransmitters and the differential effects of molindone enantiomers.

Main Results:

• Molindone (SPN-810M) demonstrated potent antagonism of dopamine D2S and D2L receptors and the serotonin 5-HT2B receptor at therapeutic concentrations.
• The observed antagonism was attributed to the parent drug, molindone, not its metabolites.
• The R(-) enantiomer of molindone showed greater potency in regulating D2S and D2L receptors compared to the S(+) enantiomer.

Conclusions:

• In vitro findings suggest molindone (SPN-810M) modulates dopamine and serotonin pathways implicated in impulsive aggression.
• These results provide a pharmacological basis for molindone's potential therapeutic effects in IA.
• Further research is warranted to confirm these findings in clinical settings.